To investigate the potential myeloproliferative role of NLRP3 in more detail, we made use of the highly aggressive AML cell line MOLM-13, which exhibits high endogenous NLRP3 expression, and generated NLRP3-deficient (ΔNLRP3) and non-targeting control (ctrl) MOLM-13 cells by CRISPR/Cas9 technology. Here, NLRP3 is linked to acute myeloid leukemia.